These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 27306534)

  • 21. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
    Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
    Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Composite criteria using clinical and FDG PET/CT factors for predicting recurrence of hepatocellular carcinoma after living donor liver transplantation.
    Kang YK; Choi JY; Paeng JC; Kim YI; Kwon HW; Cheon GJ; Suh KS; Kwon CHD; Lee DS; Kang KW
    Eur Radiol; 2019 Nov; 29(11):6009-6017. PubMed ID: 31115626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection.
    Morio K; Kawaoka T; Aikata H; Namba M; Uchikawa S; Kodama K; Ohya K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Nakamura Y; Akagi M; Awai K; Kobayashi T; Ohdan H; Chayama K
    Eur J Radiol; 2020 Mar; 124():108828. PubMed ID: 31955034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proposal of a New Preoperative Prognostic Model for Solitary Hepatocellular Carcinoma Incorporating
    Yoh T; Seo S; Ogiso S; Kawai T; Okuda Y; Ishii T; Taura K; Higashi T; Nakamoto Y; Hatano E; Kaido T; Uemoto S
    Ann Surg Oncol; 2018 Feb; 25(2):542-549. PubMed ID: 29168098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation.
    Hong G; Suh KS; Suh SW; Yoo T; Kim H; Park MS; Choi Y; Paeng JC; Yi NJ; Lee KW
    J Hepatol; 2016 Apr; 64(4):852-9. PubMed ID: 26658686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of Posttransplantation Recurrence of Hepatocellular Carcinoma Using Metabolic and Volumetric Indices of 18F-FDG PET/CT.
    Kim YI; Paeng JC; Cheon GJ; Suh KS; Lee DS; Chung JK; Kang KW
    J Nucl Med; 2016 Jul; 57(7):1045-51. PubMed ID: 26985057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization.
    Abuodeh Y; Naghavi AO; Ahmed KA; Venkat PS; Kim Y; Kis B; Choi J; Biebel B; Sweeney J; Anaya DA; Kim R; Malafa M; Frakes JM; Hoffe SE; El-Haddad G
    World J Gastroenterol; 2016 Dec; 22(47):10406-10414. PubMed ID: 28058021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients.
    Yang SH; Suh KS; Lee HW; Cho EH; Cho JY; Cho YB; Yi NJ; Lee KU
    Liver Transpl; 2006 Nov; 12(11):1655-60. PubMed ID: 16964589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preoperative FDG-PET predicts recurrence patterns in hepatocellular carcinoma.
    Kitamura K; Hatano E; Higashi T; Seo S; Nakamoto Y; Yamanaka K; Iida T; Taura K; Yasuchika K; Uemoto S
    Ann Surg Oncol; 2012 Jan; 19(1):156-62. PubMed ID: 21850564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients.
    Kim YK; Lee KW; Cho SY; Han SS; Kim SH; Kim SK; Park SJ
    Liver Transpl; 2010 Jun; 16(6):767-72. PubMed ID: 20517911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
    Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
    J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation.
    Xiao GQ; Song JL; Shen S; Yang JY; Yan LN
    World J Gastroenterol; 2014 Aug; 20(31):10953-9. PubMed ID: 25152599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio.
    Harimoto N; Shirabe K; Nakagawara H; Toshima T; Yamashita Y; Ikegami T; Yoshizumi T; Soejima Y; Ikeda T; Maehara Y
    Transplantation; 2013 Dec; 96(11):1008-12. PubMed ID: 24113512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma.
    Yaprak O; Akyildiz M; Dayangac M; Demirbas BT; Guler N; Dogusoy GB; Yuzer Y; Tokat Y
    Hepatobiliary Pancreat Dis Int; 2012 Jun; 11(3):256-61. PubMed ID: 22672818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria).
    Llovet JM; Pavel M; Rimola J; Diaz MA; Colmenero J; Saavedra-Perez D; Fondevila C; Ayuso C; Fuster J; Ginès P; Bruix J; Garcia-Valdecasas JC
    Liver Transpl; 2018 Mar; 24(3):369-379. PubMed ID: 29140601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 11C-acetate and 18F-fluorodeoxyglucose positron emission tomography/computed tomography dual imaging for the prediction of response and prognosis after transarterial chemoembolization.
    Park S; Kim TS; Kang SH; Kim HB; Park JW; Kim SK
    Medicine (Baltimore); 2018 Sep; 97(37):e12311. PubMed ID: 30212970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection.
    Lee JW; Hwang SH; Kim HJ; Kim D; Cho A; Yun M
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1984-1994. PubMed ID: 28695236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patients with non-[18 F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation.
    Kornberg A; Küpper B; Tannapfel A; Büchler P; Krause B; Witt U; Gottschild D; Friess H
    Liver Transpl; 2012 Jan; 18(1):53-61. PubMed ID: 21850692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.
    Lee JH; Park JY; Kim DY; Ahn SH; Han KH; Seo HJ; Lee JD; Choi HJ
    Liver Int; 2011 Sep; 31(8):1144-9. PubMed ID: 21745288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Living donor liver transplantation for hepatocellular carcinoma: results of prospective patient selection by Kyushu University Criteria in 7 years.
    Uchiyama H; Itoh S; Yoshizumi T; Ikegami T; Harimoto N; Soejima Y; Harada N; Morita K; Toshima T; Motomura T; Maehara Y
    HPB (Oxford); 2017 Dec; 19(12):1082-1090. PubMed ID: 28888776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.